Latest Breaking News On - Voltron therapeutics - Page 1 : comparemela.com

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases -October 05, 2023 at 08:32 am EDT

JUPITER, Fla., Oct. 05, 2023 Dyadic International, Inc. , a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein.

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center ("VIC") at Massachusetts ... | Region

JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Data Demonstrating VaxCelerate Vaccine-Induced Protection Against Viral Pathogens

/PRNewswire/ Voltron Therapeutics, a Lucius Partners portfolio company, presented new evidence that demonstrates its VaxCelerate Vaccine platform s.

Cancer Vaccines Clinical Trial Pipeline Analysis

The prevalence of cancer has been rising over the past few years, which prompts the growing demand for treatment options. The introduction of cancer.